Orphazyme
Redeye Life Science Outlook 2021: Analysts’ Top Picks (Redeye)

2021-01-21 08:47
Redeye held its Life Science Outlook 2021 earlier this week, giving its view on the sector and input on what investors should consider when looking at investments. In addition to this, Redeye's analysts presented their Top Picks of shares with a +50% potential for 2021.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Calliditas Therapeutics - I dag

{point.key}

Xbrane Biopharma - I dag

{point.key}

BONESUPPORT HOLDING - I dag

{point.key}

Orphazyme - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -